[HTML][HTML] Ending the epidemic of HIV/AIDS by 2030: Will there be an endgame to HIV, or an endemic HIV requiring an integrated health systems response in many …
Abstract The third Sustainable Development Goal (SDG-3) has a target to end the epidemic
of HIV/AIDS by 2030 (Project 2030). This will be achieved when the number of new HIV …
of HIV/AIDS by 2030 (Project 2030). This will be achieved when the number of new HIV …
HIV drug resistance in low-income and middle-income countries
After 15 years of global scale-up of antiretroviral therapy (ART), rising prevalence of HIV
drug resistance in many low-income and middle-income countries (LMICs) poses a growing …
drug resistance in many low-income and middle-income countries (LMICs) poses a growing …
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy …
M Aboud, R Kaplan, J Lombaard, F Zhang… - The Lancet infectious …, 2019 - thelancet.com
Background Doubts exist regarding optimal second-line treatment options for HIV-1-infected
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …
patients in resource-limited settings. We assessed safety and efficacy of dolutegravir …
Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency …
Abstract Background In sub-Saharan Africa, 25.5 million people are living with human
immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line …
immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line …
Viral load monitoring for people living with HIV in the era of test and treat: progress made and challenges ahead–a systematic review
Background In 2016, we conducted a systematic review to assess the feasibility of treatment
monitoring for people living with HIV (PLHIV) receiving antiretroviral therapy (ART) in low …
monitoring for people living with HIV (PLHIV) receiving antiretroviral therapy (ART) in low …
Third-line antiretroviral therapy program in the South African public sector: cohort description and virological outcomes
M Moorhouse, G Maartens, WDF Venter… - JAIDS Journal of …, 2019 - journals.lww.com
Background: The World Health Organization recommends that antiretroviral therapy (ART)
programs in resource-limited settings develop third-line ART policies. South Africa …
programs in resource-limited settings develop third-line ART policies. South Africa …
Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa
SC Inzaule, P Ondoa, T Peter, PN Mugyenyi… - The Lancet Infectious …, 2016 - thelancet.com
Increased provision of antiretroviral therapy in sub-Saharan Africa has led to a growing
number of patients with therapy failure and acquired drug-resistant HIV, driving the demand …
number of patients with therapy failure and acquired drug-resistant HIV, driving the demand …
Trends Analysis of HIV Infection and Antiretroviral Treatment Outcome in Amhara Regional from 2015 to 2021, Northeast Ethiopia
T Addisu, M Tilahun, S Wedajo… - HIV/AIDS-Research and …, 2023 - Taylor & Francis
Background The persistent efforts of HIV/AIDS epidemiology remain one of the world's most
important community health threats. To avoid becoming an epidemic, UNAIDS has set three …
important community health threats. To avoid becoming an epidemic, UNAIDS has set three …
Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa
TS Boender, RL Hamers, P Ondoa… - The Journal of …, 2016 - academic.oup.com
Background. As antiretroviral therapy (ART) programs in sub-Saharan Africa mature,
increasing numbers of persons with human immunodeficiency virus (HIV) infection will …
increasing numbers of persons with human immunodeficiency virus (HIV) infection will …
HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya
R Kantor, A DeLong, L Schreier, M Reitsma, E Kemboi… - Aids, 2018 - journals.lww.com
Objective: Characterize failure and resistance above and below guidelines-recommended
1000 copies/ml virologic threshold, upon second-line failure. Design: Cross-sectional study …
1000 copies/ml virologic threshold, upon second-line failure. Design: Cross-sectional study …